Malabsorption – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malabsorption – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of ELGN-2112 for Preterm Infants with Intestinal Malabsorption https://clinicaltrials.eu/trial/study-on-the-safety-of-elgn-2112-for-preterm-infants-with-intestinal-malabsorption/ Mon, 04 May 2026 07:57:28 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-elgn-2112-for-preterm-infants-with-intestinal-malabsorption/ This clinical trial is focused on studying the safety of a treatment called ELGN-2112 in infants with a condition known as Intestinal Malabsorption. Intestinal Malabsorption is a condition where the intestines cannot absorb nutrients properly. The treatment being tested is an oral solution containing Insulin Human, which is a protein that helps regulate blood sugar levels. The study will compare the effects of ELGN-2112 to a placebo in preterm infants born before 26 weeks of gestation and infants with Intra-Uterine Growth Restriction (IUGR), which means they are smaller than expected for their gestational age.

The purpose of the study is to assess the safety of ELGN-2112 in these specific groups of infants. Participants in the study will receive either the treatment or a placebo, and their health will be monitored over a period of time. The study will look at various factors, such as how long it takes for the infants to achieve full feeding through the intestines, the occurrence of a serious intestinal condition called Necrotizing Enterocolitis (NEC), and the number of days until they can be discharged from the hospital. The study will also track other health outcomes, including the incidence of infections and the infants’ growth and development.

This trial is designed to provide important information about the safety of ELGN-2112 in helping infants with Intestinal Malabsorption and related conditions. By participating in this study, researchers hope to better understand how this treatment can support the health and development of these vulnerable infants.

]]> Study on the Effects of ELGN-2112 (Human Insulin) for Treating Intestinal Malabsorption in Preterm Infants https://clinicaltrials.eu/trial/study-on-the-effects-of-elgn-2112-human-insulin-for-treating-intestinal-malabsorption-in-preterm-infants/ Wed, 29 Apr 2026 14:22:39 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-elgn-2112-human-insulin-for-treating-intestinal-malabsorption-in-preterm-infants/ This clinical trial is focused on studying intestinal malabsorption in preterm infants. Intestinal malabsorption is a condition where the intestines cannot absorb nutrients properly, which can be particularly challenging for infants born prematurely. The study will evaluate the effects of a treatment called ELGN-2112, which is an oral solution containing insulin human. Insulin human is a protein that is commonly used to help regulate blood sugar levels, but in this study, it is being tested for its potential benefits in improving nutrient absorption in the intestines of preterm infants.

The purpose of the study is to assess how effective and safe ELGN-2112 is compared to a placebo in helping preterm infants reach full enteral feeding. Enteral feeding refers to delivering nutrition directly to the stomach or intestines, which is crucial for the growth and development of preterm infants. The study will involve two groups of infants: one group will receive the ELGN-2112 treatment, and the other group will receive a placebo. The main goal is to see how quickly infants can achieve full enteral feeding, defined as consuming at least 150 ml/kg/day for three consecutive days.

Throughout the study, researchers will monitor various aspects of the infants’ health, including the time it takes to wean off parenteral nutrition (nutrition given through a vein), the occurrence of a serious intestinal condition called necrotizing enterocolitis (NEC), and the overall time to discharge from the hospital. The study aims to provide valuable insights into whether ELGN-2112 can help improve the health outcomes of preterm infants with intestinal malabsorption.

]]>